Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex is a clinical stage macrophage reprogramming immunotherapy company focused on developing its lead product Allocetra for the treatment of osteoarthritis. With its RAIN protocol and AI agent-ready interface, the company is poised to take advantage of the growing interest in prediction markets, allowing for efficient and speedy creation of live prediction markets. Additionally, the company's option to purchase up to $918M worth of RAIN tokens at a discounted price creates a significant potential future value driver, which is not currently factored into the company's market valuation.

Bears say

Enlivex is currently focused on developing Allocetra, a therapy for osteoarthritis, while also utilizing the RAIN protocol as its primary treasury reserve. Despite the potential for token appreciation and recent PIPE transaction, Enlivex may face challenges in the future with the RAIN token's "buy and burn" mechanism potentially leading to a decrease in value. This, combined with its focus on only one clinical program, raises concerns about the company's overall financial stability and may lead to a decline in stock performance.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.